Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs

Diabetes Res Clin Pract. 2012 Jun;96(3):e66-9. doi: 10.1016/j.diabres.2012.02.005. Epub 2012 Mar 14.

Abstract

Endpoint HbA(1c) <7.0% was achieved by 80 (73.4%) lispro mix 25 (LM25)-treated patients and 67 (60.9%) glargine-treated patients (p=0.027) with baseline 1,5 anhydroglucitol (1,5AG) below median and 75 (70.8%) LM25-treated patients and 72 (63.7%) glargine-treated patients (p=0.238) with 1,5AG≥median, suggesting, 1,5AG may offer therapeutic insight when starting insulin therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose / drug effects
  • Blood Glucose / metabolism*
  • Deoxyglucose / administration & dosage
  • Deoxyglucose / therapeutic use*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hypoglycemia / blood
  • Hypoglycemia / drug therapy*
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use*
  • Insulin Glargine
  • Insulin Lispro / administration & dosage
  • Insulin Lispro / therapeutic use*
  • Insulin, Long-Acting / administration & dosage
  • Insulin, Long-Acting / therapeutic use*
  • Male
  • Middle Aged
  • Treatment Outcome
  • Weight Gain / drug effects

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin Lispro
  • Insulin, Long-Acting
  • Insulin Glargine
  • 1,5-anhydroglucitol
  • Deoxyglucose